

PODIUM PRESENTATION ABSTRACTS



83. The More You Use the Brace, the Better the Results: the Dose-Response Curves Between 18 and 23 Hours/day Brace-Wearing in 687 Braist-Matched Children §

Stefano Negrini, MD; Greta Jurenait, MD; Fabio Zaina, MD

Hypothesis

A dose-response curve exists also for brace wear >18 hours/day (h/d)

Design

Secondary analysis of a retrospective study from a prospective database

Introduction

The Brace Adolescent Idiopathic Scoliosis Trial (BrAIST) dose-response curve (outcome: end-of-treatment [EoT] <50°) drives many to prescribe braces no more than 18 h/d. The SOSORT Guidelines add three other outcomes: improvement >5°, no progression >5° and EoT<30° (to avoid health issues in adulthood)

Methods

The cohort was prospectively recruited in 15 years, with patients using thermal sensors in the last 10. The braces (SOSORT-SRS-POSNA classification) included: 1) anterior closure 3D push-up TLSO, monocot rigid or bivalve highly-rigid; 2) for thoracolumbar and lumbar curves, the LSO version, or a ventral closure fronto-transverse plane detorsion monocot rigid LSO. Our protocols prescribe increasing brace rigidity and h/d (range 18-24) with a worsening prognosis. We subgrouped for brace rigidity and h/d prescribed, reported or recorded. We developed four dose-response curves for the SOSORT outcomes using BrAIST methods. We checked baseline differences among h/d quartiles (ANOVA), and calculated the percentage (95% confidence intervals) of participants for each outcome (chi2 test). For the outcome EoT<30°, we considered the rate change of participants <30° between start and EoT


Results

We included 670 consecutive patients (413 with thermosen-

sors), 30±6 °Cobb, 83% females, age 13.0±1.3, Risser 1±1. The highest h/d quartiles showed the best °Cobb results even if they included (in agreement with our protocols) statistically significantly worse patients for °Cobb, ATR, and TRACE. The dose-response curves were statistically significant for EoT<30° and improvement outcomes. EoT<50° and no progression outcomes showed a high success rate (98% and 87%, respectively) and no dose-response effect

Conclusion

In a BrAIST-matched population with brace prescription >18 h/d, we found a dose-response effect for the most ambitious outcomes (improvement and EoT<30°), even if the higher h/d quartiles included the most demanding scoliosis. The high success rate for no progression and EoT<50° in this population reduces/abolishes the clinical importance of the dose-response curve. Our results support changing the 18 h/d brace prescription paradigm



Patients	Bracing time - TRACE	ATR	Compliance	Change Cobb	Improved	Not progressed	Change in rate <30°	End 50°	N	Significances
Total	670	13.3-23.2 (20.75)	100	13.0±1.3	30±6	83	1±1	100	670	
First quartile	168	13.3-17.9 (20.75)	97.5%	13.0±1.3	30±6	83	1±1	100	335/670 (50%)	
Second quartile	168	17.9-21.0 (22.0)	98.1%	18.0±1.4	30±6	83	1±1	100	335/670 (50%)	
Third quartile	168	21.0-23.2 (22.0)	98.5%	21.0±1.4	30±6	83	1±1	100	335/670 (50%)	
Fourth quartile	168	23.2-23.2 (22.0)	98.8%	23.2±0.2	30±6	83	1±1	100	335/670 (50%)	

Data and curves in the thermosensors subgroup

§ = Hibbs Award Nominee – Best Clinical Paper

SRS 60THANNUAL MEETING | September 16-20, 2025 | CHARLOTTE, NORTH CAROLINA